Xue Ying-Chao, Liu Xiao-Long, Liu Bo-Yu, Zhang Sheng-Xiang, Xu Qi-Hua, Wu Ling-Dan
The Affiliated Eye Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, Jiangxi Province, China.
School of Optometry, Jiangxi Medical College, Nanchang University, Nanchang 330031, Jiangxi Province, China.
Int J Ophthalmol. 2025 Jun 18;18(6):1146-1151. doi: 10.18240/ijo.2025.06.22. eCollection 2025.
Artesunate is a derivative of artemisinin, and due to its high solubility, and it has a broader application in clinical settings. Extensive research has confirmed that artemisinin-based drugs show significant activities in anti-inflammatory, anti-tumor, anti-viral, and anti-angiogenesis aspects, suggesting that artesunate might have potential in treating retinal diseases. Currently, the etiology of most retinal diseases is not fully understood, and there is a lack of effective treatment methods. This paper summarized the research progress of artesunate in the treatment of retinal diseases, including retinoblastoma, choroidal melanoma, diabetic retinopathy, central retinal vein occlusion, proliferative retinopathy, and ocular neovascularization. In addition, the potential applications and future research directions of artesunate in the treatment of retinal diseases were also discussed.
青蒿琥酯是青蒿素的衍生物，因其具有高溶解性，在临床环境中有更广泛的应用。广泛研究证实，以青蒿素为基础的药物在抗炎、抗肿瘤、抗病毒和抗血管生成方面表现出显著活性，这表明青蒿琥酯在治疗视网膜疾病方面可能具有潜力。目前，大多数视网膜疾病的病因尚未完全明确，且缺乏有效的治疗方法。本文综述了青蒿琥酯在治疗视网膜疾病方面的研究进展，包括视网膜母细胞瘤、脉络膜黑色素瘤、糖尿病视网膜病变、视网膜中央静脉阻塞、增殖性视网膜病变和眼部新生血管形成。此外，还讨论了青蒿琥酯在治疗视网膜疾病方面的潜在应用和未来研究方向。
